We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $11.7B
1-Year Est. Return 174.13%
This Fund
S&P 500
This Quarter Est. Return
+30.25%
1 Year Est. Return
+174.13%
3 Year Est. Return
+466.81%
5 Year Est. Return
+622.69%
10 Year Est. Return
+19,772.83%
AUM
$574M
AUM Growth
+$99.8M
Cap. Flow
-$7.21M
Cap. Flow %
-1.26%
Top 10 Hldgs %
75.45%
Holding
31
New
3
Increased
10
Reduced
12
Closed
4

Top Buys

Rank Stock Value
1
ACHN
Achillion Pharmaceuticals
ACHN
+$27.7M
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$8.1M
3
RGNX icon
Regenxbio
RGNX
+$5.99M
4
PTCT icon
PTC Therapeutics
PTCT
+$3.74M
5
BMY icon
Bristol-Myers Squibb
BMY
+$3.09M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$35.6M
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$10.8M
3
ATRA icon
Atara Biotherapeutics
ATRA
+$7.79M
4
OMER icon
Omeros
OMER
+$4.73M
5
UHS icon
Universal Health Services
UHS
+$3.15M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
2 Miscellaneous 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
1
Alnylam Pharmaceuticals
ALNY
$31.7B
$73.2M 12.75%
623,338
-417,269
-40% -$35.6M
PTCT icon
2
PTC Therapeutics
PTCT
$5.85B
$69.9M 12.18%
3,495,143
+190,929
+6% +$3.74M
BMY icon
3
Bristol-Myers Squibb
BMY
$136B
$52.7M 9.19%
827,512
+52,837
+7% +$3.09M
RGNX icon
4
Regenxbio
RGNX
$638M
$50.7M 8.83%
1,539,005
+266,235
+21% +$5.99M
AVXS
5
DELISTED
AveXis, Inc. Common Stock
AVXS
$45.2M 7.88%
467,667
-119,450
-20% -$10.8M
LJPC
6
DELISTED
La Jolla Pharmaceutical Company
LJPC
$36.3M 6.33%
1,044,307
-63,072
-6% -$2.03M
ACHN
7
DELISTED
Achillion Pharmaceuticals
ACHN
$35.2M 6.13%
7,839,766
+6,249,312
+393% +$27.7M
ABUS icon
8
Arbutus Biopharma
ABUS
$1B
$32.7M 5.69%
5,266,280
+56,457
+1% +$241K
AGEN
9
Agenus
AGEN
$345M
$18.6M 3.24%
214,934
-3,002
-1% -$243K
CORI
10
DELISTED
Corium International, Inc.
CORI
$18.6M 3.23%
1,675,479
+43,478
+3% +$385K
BCRX icon
11
BioCryst Pharmaceuticals
BCRX
$2.51B
$17.4M 3.03%
3,324,705
-9,253
-0.3% -$47.4K
OXFD
12
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$17.3M 3.02%
1,032,370
+185,453
+22% +$3.02M
BLUE
13
DELISTED
bluebird bio
BLUE
$14.3M 2.49%
8,035
-23
-0.3% -$32.1K
OSUR icon
14
OraSure Technologies
OSUR
$248M
$12.1M 2.1%
535,707
-52,549
-9% -$1.06M
DRNA
15
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$12M 2.08%
2,078,991
– –
TCMD icon
16
Tactile Systems Technology
TCMD
$525M
$10.9M 1.9%
353,216
-19,086
-5% -$604K
MYOK
17
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$10.9M 1.9%
+253,962
New +$8.1M
ATRA icon
18
Atara Biotherapeutics
ATRA
$92.3M
$10.9M 1.89%
26,241
-20,669
-44% -$7.79M
MASI
19
DELISTED
Masimo
MASI
$10.5M 1.82%
120,900
+20,000
+20% +$1.77M
VIVE
20
DELISTED
VIVEVE MED INC
VIVE
$7.72M 1.34%
1,473
+234
+19% +$1.44M
VRAY
21
DELISTED
ViewRay, Inc.
VRAY
$5.88M 1.02%
1,020,462
+256,127
+34% +$1.44M
FSTX
22
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$4.2M 0.73%
62,274
-226
-0.4% -$12.9K
APYX icon
23
Apyx Medical
APYX
$130M
$3.85M 0.67%
+1,139,600
New +$2.94M
ZYNE
24
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$1.67M 0.29%
+200,000
New +$2.11M
GBT
25
DELISTED
Global Blood Therapeutics, Inc.
GBT
$817K 0.14%
26,310
-67
-0.3% -$1.88K
1
2

Similar funds

CIM
Centersquare Investment Management Conshohocken, Pennsylvania $11.7B AUM 20.39% 1-Year Est. Return
MIF
Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
UE
Unisphere Establishment Vaduz, Liechtenstein $11.7B AUM 0.31% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return
FPAS
Focus Partners Advisor Solutions Saint Louis, Missouri $11.8B AUM 25.68% 1-Year Est. Return
CCMT
CMT Capital Markets Trading Frankfurt, Germany $11.8B AUM 39.43% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

RTW Investments's Q3 2017 Portfolio in Review

As of Q3 2017, RTW Investments held 31 positions worth $574M, up 21% from $474M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

RTW Investments's Q3 2017 filing shows 3 new, 10 increased, 12 reduced and 4 closed positions. Its largest new stake was MyoKardia, Inc. Common Stock: 253,962 shares worth $10.9M. The largest sale was Alnylam Pharmaceuticals, an estimated $35.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

  • RTW Investments's largest Q3 2017 buy was MyoKardia, Inc. Common Stock: 253,962 shares worth $10.9M.
  • RTW Investments added most to Achillion Pharmaceuticals in Q3 2017, an estimated $27.7M increase.
  • RTW Investments's biggest Q3 2017 reduction was Alnylam Pharmaceuticals, cutting an estimated $35.6M.
  • RTW Investments fully exited Omeros in Q3 2017, selling an estimated $4.73M.
  • RTW Investments's ten largest holdings make up 75% of its $574M portfolio in Q3 2017.
  • RTW Investments opened 3 new positions and closed 4 in Q3 2017.
  • RTW Investments's portfolio value rose 21% quarter-over-quarter to $574M.

Based on RTW Investments's 13F filing for Q3 2017, filed 14 Nov 2017.